NCT00612820View on ClinicalTrials.gov

A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)

PHASE2CompletedINTERVENTIONAL

Enrollment

55

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Rhinitis, Allergic, Seasonal

Interventions

DRUG

GSK256066

200mcg bd,

DRUG

fluticasone propionate

200mcg od,100mcg bd

Trial Locations (1)

A-1150

GSK Investigational Site, Vienna

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00612820 - A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR) | Biotech Hunter | Biotech Hunter